Literature DB >> 9043101

Plasma levels of protoporphyrin IX in humans after oral administration of 5-aminolevulinic acid.

J Webber1, D Kessel, D Fromm.   

Abstract

We report on the pharmacokinetics of PP formation and elimination in 4 patients after the administration of oral ALA (60 mg kg-1). After a brief distribution phase, plasma PP levels decline (half life = 8 h) and was almost undetectable by 48 h post-administration. This confirms pharmacokinetic clinical data which show that ALA in a shortened interval of skin photosensitization compared with other sensitizers such as Photofrin and 'HPD'. A brief summary of other clinical-toxicity findings is reported.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9043101     DOI: 10.1016/s1011-1344(96)07348-4

Source DB:  PubMed          Journal:  J Photochem Photobiol B        ISSN: 1011-1344            Impact factor:   6.252


  9 in total

Review 1.  BODIPY dyes in photodynamic therapy.

Authors:  Anyanee Kamkaew; Siang Hui Lim; Hong Boon Lee; Lik Voon Kiew; Lip Yong Chung; Kevin Burgess
Journal:  Chem Soc Rev       Date:  2012-09-26       Impact factor: 54.564

2.  Interference with the Jaffé method for creatinine following 5-aminolevulinic acid administration.

Authors:  Harry Quon; Craig E Grossman; Rebecca L King; Mary Putt; Keri Donaldson; Larry Kricka; Jarod Finlay; Timothy Zhu; Andrea Dimofte; Kelly Malloy; Keith A Cengel; Theresa M Busch
Journal:  Photodiagnosis Photodyn Ther       Date:  2010-08-30       Impact factor: 3.631

3.  The proton-coupled oligopeptide transporter 1 plays a major role in the intestinal permeability and absorption of 5-aminolevulinic acid.

Authors:  Yehua Xie; Yongjun Hu; David E Smith
Journal:  Br J Pharmacol       Date:  2015-11-25       Impact factor: 8.739

4.  Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications.

Authors:  F Döring; J Walter; J Will; M Föcking; M Boll; S Amasheh; W Clauss; H Daniel
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

5.  Clinical Pharmacokinetics and Safety of a 10% Aminolevulinic Acid Hydrochloride Nanoemulsion Gel (BF-200 ALA) in Photodynamic Therapy of Patients Extensively Affected With Actinic Keratosis: Results of 2 Maximal Usage Pharmacokinetic Trials.

Authors:  Ben Novak; Janet DuBois; Osama Chahrour; Tamara Papusha; Stefan Hirt; Thomas Philippi; Corinna Zogel; Katharina Osenberg; Beate Schmitz; Hermann Lübbert
Journal:  Clin Pharmacol Drug Dev       Date:  2021-10-11

6.  Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: a multicenter retrospective study.

Authors:  Hideo Fukuhara; Takahiro Nohara; Koshiro Nishimoto; Yutaka Hatakeyama; Yuki Hyodo; Yoshiyasu Okuhara; Masafumi Oyama; Atsushi Mizokami; Keiji Inoue; Hideyasu Matsuyama
Journal:  BMC Cancer       Date:  2021-11-13       Impact factor: 4.430

7.  Intraoperative fluorescence imaging with aminolevulinic acid detects grossly occult breast cancer: a phase II randomized controlled trial.

Authors:  Kathryn Ottolino-Perry; Anam Shahid; Stephanie DeLuca; Viktor Son; Mayleen Sukhram; Fannong Meng; Zhihui Amy Liu; Sara Rapic; Nayana Thalanki Anantha; Shirley C Wang; Emilie Chamma; Christopher Gibson; Philip J Medeiros; Safa Majeed; Ashley Chu; Olivia Wignall; Alessandra Pizzolato; Cheryl F Rosen; Liis Lindvere Teene; Danielle Starr-Dunham; Iris Kulbatski; Tony Panzarella; Susan J Done; Alexandra M Easson; Wey L Leong; Ralph S DaCosta
Journal:  Breast Cancer Res       Date:  2021-07-12       Impact factor: 6.466

8.  Photodynamic diagnosis of ovarian cancer using hexaminolaevulinate: a preclinical study.

Authors:  F Lüdicke; T Gabrecht; N Lange; G Wagnières; H Van Den Bergh; L Berclaz; A L Major
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

9.  Targets and mechanisms of photodynamic therapy in lung cancer cells: a brief overview.

Authors:  Angela Chiaviello; Ilaria Postiglione; Giuseppe Palumbo
Journal:  Cancers (Basel)       Date:  2011-03-03       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.